Sign in

Research summary ·

Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology-A Systematic Review.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This review looked at GLP-1 drugs and male hormones and fertility. The men had obesity or type 2 diabetes, often with low testosterone. The authors searched PubMed, Cochrane and Google Scholar from January 2021 to January 2026. The studies included one randomised placebo-controlled crossover trial.

What they found

Some men had obesity, type 2 diabetes or low testosterone from metabolic causes. In them, the drugs were linked to modest rises in testosterone. Erectile function and some semen measures also improved. In healthy men, a placebo-controlled trial found no significant effects. Responses seemed to depend on starting metabolic health.

What it means for patients

The authors link GLP-1 drugs to better hormone health in men with metabolic problems. They say the drugs were neutral in healthy men.

Why it is not certain yet

Only one study was a randomised trial. These studies show links, not cause. The authors say larger prospective studies are needed. A review can only be as good as the studies in it.

Source

Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology-A Systematic Review.

PubMed · PMID 42587729

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Obesity publications